Patients with pathologically confirmed malignant pleural or peritoneal mesothelioma (MPM), non-small cell lung cancer (NSCLC), ovarian cancer or cholangiocarcinoma were eligible if they had progressive disease despite standard of care therapy; if they had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; and if their tumors expressed mesothelin in ≥50% of tumor cells with a 2+ and/or 3+ intensity, as determined by central immunohistochemistry (IHC) assessment. Here, MSLN is linked to neoplasm.